Acute renal toxicity associated with suramin in the treatment of prostate cancer

William D. Figg, Michael R. Cooper, Alain Thibault, Donna Headlee, Jeffrey Humphrey, Raymond C. Bergan, Eddie Reed, Oliver Sartor

Research output: Contribution to journalArticle

28 Scopus citations


The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

Original languageEnglish (US)
Pages (from-to)1612-1614
Number of pages3
Issue number5
StatePublished - Sep 1 1994



  • acute renal failure
  • nephrotoxicity
  • prostate cancer
  • renal
  • suramin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this